Other Events ·
NovaBridge in-licenses VIS-102 for up to $111M from Hiteck
IMABNovaBridge Biosciences
Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences, entered into an exclusive license agreement with Wuhan Hiteck Biological Pharma Co., Ltd. on October 13, 2026, for the development and commercialization of VIS-102 (HT006.2.2) worldwide, excluding Greater China. Visara will pay Hiteck a $7.0 million upfront payment and is obligated to make additional aggregate milestone payments of up to $104.0 million based on clinical and commercial achievements. The agreement also includes tiered royalties on net sales. VIS-102 is an investigational modified recombinant human nerve growth factor therapy designed to treat neurotrophic keratitis, a rare degenerative eye disease. NovaBridge Biosciences operates as a global biotechnology company advancing therapeutic programs in oncology and ophthalmology.